Arcus Biosciences Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| ARCUS BIOSCIENCES, INC. | ||
| Date: February 25, 2025 | By: | /s/ Terry Rosen |
|---|---|---|
| Terry Rosen, Ph.D. | ||
| Chief Executive Officer(Principal Executive Officer and Duly Authorized Officer) | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS that each person whose signature appears below constitutes and appoints Terry Rosen, Ph.D. and Robert C. Goeltz II, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Terry Rosen | Chief Executive Officer and Director | February 25, 2025 |
| Terry Rosen, Ph.D. | (Principal Executive Officer) | |
| /s/ Robert C. Goeltz II | Chief Financial Officer | February 25, 2025 |
| Robert C. Goeltz II | (Principal Financial Officer) | |
| /s/ Alexander Azoy | Chief Accounting Officer | February 25, 2025 |
| Alexander Azoy | (Principal Accounting Officer) | |
| /s/ Dietmar Berger | Director | February 25, 2025 |
| Dietmar Berger, M.D., Ph.D. | ||
| /s/ Kathryn Falberg | Director | February 25, 2025 |
| Kathryn Falberg | ||
| /s/ Linda Higgins | Director | February 25, 2025 |
| Linda Higgins, Ph.D. | ||
| /s/ Yasunori Kaneko | Director | February 25, 2025 |
| Yasunori Kaneko, M.D. | ||
| /s/ David Lacey | Director | February 25, 2025 |
| David Lacey, M.D. | ||
| /s/ Nicole Lambert | Director | February 25, 2025 |
| Nicole Lambert | ||
| /s/ Patrick Machado | Director | February 25, 2025 |
| Patrick Machado, J.D. | ||
| /s/ Johanna Mercier | Director | February 25, 2025 |
| Johanna Mercier | ||
| /s/ Andrew Perlman | Director | February 25, 2025 |
| Andrew Perlman, M.D., Ph.D. | ||
| /s/ Antoni Ribas | Director | February 25, 2025 |
| Antoni Ribas, M.D., Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.